​
The image represents the mechanism of action of Tirzepatide. Image courtesy: Rabbani et al., 2024
Invention Summary:
Congenital generalized lipodystrophy (CGL) is a rare autosomal recessive disorder, affecting approximately 1 in 10 million people in the USA. It is characterized by a total loss of adipose tissue and leptin, leading to severe insulin resistance and diabetes. Leptin replacement therapy using Metreleptin is the only currently available treatment, but it requires daily painful injections and is costly. Therefore, a more affordable and better-tolerated alternative is needed.
Rutgers researchers demonstrate tirzepatide as an alternative to Metreleptin for treating CGL patients. Eli Lilly has received FDA approval to market tirzepatide for obesity and diabetes management under the brand name Mounjaro. Tirzepatide is relatively cheaper and is a long-acting incretin analog, a metabolic hormone that activates both GLP-1 and GIP receptors, improving blood sugar control, lowering triglycerides, and increasing adiponectin. Having tested in CGL patients, this makes tirzepatide a more affordable and better-tolerated treatment option for them.
Market Applications:
- Tirzepatide treats Congenital Generalized Lipodystrophy
Advantages:
- Cost-effective: Tirzepatide is a more economical alternative to Metreleptin for CGL patients.
- Long acting: Requires less frequent administration compared to daily Metreleptin painful injections.
- Multiple benefits: Improves blood sugar control, reduces triglycerides, and increases adiponectin levels.
Intellectual Property & Development Status: This is an advanced-stage technology where the inventors have tested tirzepatide in CGL patients. Patent pending. For any business development and other collaborative partnerships contact marketingbd@research.rutgers.edu
